Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of HRS-9821 in Healthy Subjects and Patients With COPD
NCT07116915Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HRS-9821 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Change from baseline in the rate of adverse events up to 40 days. Started Aug 2025; status: completed.
02
Drugs
HRS-9821
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07116915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116915.